The post Eli Lilly to build $6 billion Alabama manufacturing plant appeared on BitcoinEthereumNews.com. Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend $6 billion to build a manufacturing plant in Huntsville, Alabama, to help boost production of its closely watched experimental obesity pill and other drugs.  It is the third facility in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020. The company said it expects construction of the Alabama plant to start in 2026 and for it to be completed in 2032.  “Today’s investment continues the onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S.,” said Eli Lilly CEO David Ricks in a release.  That added production capacity for Eli Lilly’s obesity pill, orforglipron, is crucial as the company races to file for its approval and tries to maintain its dominance in the booming market for GLP-1s. The company and its chief rival, Novo Nordisk, faced supply shortages for their existing weekly injections after demand skyrocketed in the U.S. in recent years, though they have managed to alleviate those issues. Eli Lily’s pill in November won a priority review voucher from the Food and Drug Administration, which will significantly speed up the regulator’s assessment of the drug to potentially a few months.  Drugmakers have been scrambling to boost their production in the U.S. after threats by President Donald Trump to impose tariffs on pharmaceuticals… The post Eli Lilly to build $6 billion Alabama manufacturing plant appeared on BitcoinEthereumNews.com. Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend $6 billion to build a manufacturing plant in Huntsville, Alabama, to help boost production of its closely watched experimental obesity pill and other drugs.  It is the third facility in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020. The company said it expects construction of the Alabama plant to start in 2026 and for it to be completed in 2032.  “Today’s investment continues the onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S.,” said Eli Lilly CEO David Ricks in a release.  That added production capacity for Eli Lilly’s obesity pill, orforglipron, is crucial as the company races to file for its approval and tries to maintain its dominance in the booming market for GLP-1s. The company and its chief rival, Novo Nordisk, faced supply shortages for their existing weekly injections after demand skyrocketed in the U.S. in recent years, though they have managed to alleviate those issues. Eli Lily’s pill in November won a priority review voucher from the Food and Drug Administration, which will significantly speed up the regulator’s assessment of the drug to potentially a few months.  Drugmakers have been scrambling to boost their production in the U.S. after threats by President Donald Trump to impose tariffs on pharmaceuticals…

Eli Lilly to build $6 billion Alabama manufacturing plant

2025/12/10 22:37

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images)

Raquel Natalicchio | Houston Chronicle | Getty Images

Eli Lilly on Tuesday said it will spend $6 billion to build a manufacturing plant in Huntsville, Alabama, to help boost production of its closely watched experimental obesity pill and other drugs. 

It is the third facility in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020.

The company said it expects construction of the Alabama plant to start in 2026 and for it to be completed in 2032. 

“Today’s investment continues the onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S.,” said Eli Lilly CEO David Ricks in a release. 

That added production capacity for Eli Lilly’s obesity pill, orforglipron, is crucial as the company races to file for its approval and tries to maintain its dominance in the booming market for GLP-1s. The company and its chief rival, Novo Nordisk, faced supply shortages for their existing weekly injections after demand skyrocketed in the U.S. in recent years, though they have managed to alleviate those issues.

Eli Lily’s pill in November won a priority review voucher from the Food and Drug Administration, which will significantly speed up the regulator’s assessment of the drug to potentially a few months. 

Drugmakers have been scrambling to boost their production in the U.S. after threats by President Donald Trump to impose tariffs on pharmaceuticals imported into the U.S. But concerns about those potential tariffs have eased following recent drug pricing deals with Trump that exempt companies from the levies.

Eli Lilly said the Alabama site will bring 450 jobs to the area, including engineers, scientists, operations personnel and lab technicians, as well as 3,000 construction jobs. 

Source: https://www.cnbc.com/2025/12/09/eli-lilly-6-billion-alabama-manufacturing-plant-obesity-pill.html

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Aave DAO to Shut Down 50% of L2s While Doubling Down on GHO

Aave DAO to Shut Down 50% of L2s While Doubling Down on GHO

The post Aave DAO to Shut Down 50% of L2s While Doubling Down on GHO appeared on BitcoinEthereumNews.com. Aave DAO is gearing up for a significant overhaul by shutting down over 50% of underperforming L2 instances. It is also restructuring its governance framework and deploying over $100 million to boost GHO. This could be a pivotal moment that propels Aave back to the forefront of on-chain lending or sparks unprecedented controversy within the DeFi community. Sponsored Sponsored ACI Proposes Shutting Down 50% of L2s The “State of the Union” report by the Aave Chan Initiative (ACI) paints a candid picture. After a turbulent period in the DeFi market and internal challenges, Aave (AAVE) now leads in key metrics: TVL, revenue, market share, and borrowing volume. Aave’s annual revenue of $130 million surpasses the combined cash reserves of its competitors. Tokenomics improvements and the AAVE token buyback program have also contributed to the ecosystem’s growth. Aave global metrics. Source: Aave However, the ACI’s report also highlights several pain points. First, regarding the Layer-2 (L2) strategy. While Aave’s L2 strategy was once a key driver of success, it is no longer fit for purpose. Over half of Aave’s instances on L2s and alt-L1s are not economically viable. Based on year-to-date data, over 86.6% of Aave’s revenue comes from the mainnet, indicating that everything else is a side quest. On this basis, ACI proposes closing underperforming networks. The DAO should invest in key networks with significant differentiators. Second, ACI is pushing for a complete overhaul of the “friendly fork” framework, as most have been unimpressive regarding TVL and revenue. In some cases, attackers have exploited them to Aave’s detriment, as seen with Spark. Sponsored Sponsored “The friendly fork model had a good intention but bad execution where the DAO was too friendly towards these forks, allowing the DAO only little upside,” the report states. Third, the instance model, once a smart…
Share
BitcoinEthereumNews2025/09/18 02:28